MEC Plus

Burkitt Lymphoma
Burkitt Lymphoma
Leidy Isenalumhe, MD
Double Hit Lymphomas
Double Hit Lymphomas
Julio Chavez, MD, MS
CNS Lymphomas
CNS Lymphomas
Sepideh Mokhtari, MD
Current Standard of Therapies in CLL
Current Standard of Therapies in CLL
Javier Pinilla-Ibarz, MD, PhD
New Strategies for MCL
New Strategies for MCL
Bijal Shah, MD, MS
Marginal Zone Lymphomas
Marginal Zone Lymphomas
Sameh Gaballa, MD
Current Status of Cervical Cancer Screening
Current Status of Cervical Cancer Screening
Ritu Salani MD, MBA
Role of ADCs in Gynecological Malignancies
Role of ADCs in Gynecological Malignancies
Don S. Dizon, MD, FACP, FASCO
Ovarian Cancer: Beyond Carboplatin and Paclitaxel
Ovarian Cancer: Beyond Carboplatin and Paclitaxel
Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS
Endocrine Therapy for Advanced Breast Cancer: Current and Future Strategies
Endocrine Therapy for Advanced Breast Cancer: Current and Future Strategies
Reshma L. Mahtani, DO
Endocrine Therapy and Targeted Agents for Early-Stage HR+ Breast Cancer
Endocrine Therapy and Targeted Agents for Early-Stage HR+ Breast Cancer
William J. Gradishar, MD, FACP
Antibody Drug Conjugates: New Agents and Optimal Sequencing
Antibody Drug Conjugates: New Agents and Optimal Sequencing
Hope S. Rugo, MD, FASCO
Immunotherapy for Breast Cancer: Updates and New Directions
Immunotherapy for Breast Cancer: Updates and New Directions
Mark Pegram, MD
Prostate Cancer: Role of PSMA PET and Accurately Defining “Neuroendocrine” Prostate
Prostate Cancer: Role of PSMA PET and Accurately Defining “Neuroendocrine” Prostate
Ravi A. Madan, MD
Role of Immunotherapy in HNC
Role of Immunotherapy in HNC
Hyunseok (Hyu) Kang, MD, MPH, FACP
Renal Cell Carcinoma (RCC): Current Approach to First Line Therapy and Beyond
Renal Cell Carcinoma (RCC): Current Approach to First Line Therapy and Beyond
Petros Grivas, MD, PhD
Adjuvant and Neo-adjuvant Therapy for Lung Cancer
Adjuvant and Neo-adjuvant Therapy for Lung Cancer
Janakiraman Subramanian MD, MPH
Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)
Other Targetable Agents (KRASg 12c, BRafv600, RET and NTRK)
Edgardo S. Santos Castillero, MD, FACP
Approach to NSCLC With Targetable Mutations (EGFR, ALK and ROS-1)
Approach to NSCLC With Targetable Mutations (EGFR, ALK and ROS-1)
Jorge J Nieva, M.D.
Approach to NSCLC Without Targetable Mutations
Approach to NSCLC Without Targetable Mutations
Luis E. Raez, MD, FACP, FCCP
Liquid Biopsy: Advances in the Last Decade and Future Directions
Liquid Biopsy: Advances in the Last Decade and Future Directions
Edgardo S. Santos Castillero, MD, FACP
Melanoma as a Paradigm for the Future of Immunotherapy
Melanoma as a Paradigm for the Future of Immunotherapy
Paolo A. Ascierto, MD
Novel Immunotherapy Approaches in Hepatobiliary Malignancies
Novel Immunotherapy Approaches in Hepatobiliary Malignancies
Rachna T. Shroff, MD, MS
Pancreatic Cancer: Are We Finally Making Progress?
Pancreatic Cancer: Are We Finally Making Progress?
Andrew H. Ko, MD, FASCO